TABLE 3.

Factors Predicting Serostatus Following Vaccine Dose 2 in Best Performing Model

	Control group	Test group	OR (95% CI)
DMT	No impact on vaccine response in univariate model a	Anti‐CD20 mAb b	0.03 (0.01–0.06) c
Vaccine type	AstraZeneca	Pfizer	2.65 (1.27–5.52) d
Gender	Female	Male	1.08 (0.49–2.41)
Age			1.03 (1.00–1.06) e
Prior COVID symptoms	No COVID symptoms	Prior COVID symptoms	1.00 (0.31–3.18)
EDSS	EDSS 0.0–4.0	EDSS 4.5–5.5	2.28 (0.52–10.04)
		EDSS 6.0–6.5	0.63 (0.18–2.14)
		EDSS 7.0–10.0	0.27 (0.03–2.86)
Days from anti‐CD20 b to vaccine		Anti‐CD20 mAb b	1.00 (0.99–1.01)
Total time on DMT			1.00 (0.00–1.00)
Lymphocyte count			1.15 (0.68–1.95)
Time between vaccine doses			1.00 (0.89–1.14)
Time between vaccine and sample			0.85 (0.73–0.99) e

^a Includes no DMT, natalizumab, alemtuzumab, dimethyl fumarate, cladribine, glatiramer acetate, interferon beta, and teriflunomide.

^b Ocrelizumab and rituximab; ofatumumab excluded.

^c p < 0.001.

^d p < 0.01.

^e p = 0.04; NS on correction for multiple testing.

CI = confidence interval; COVID‐19 = coronavirus disease 2019; DMT = disease modifying therapy; EDSS = Expanded Disability Status Scale; mAb = monoclonal antibody; OR = odds ratio.